“Bedaquiline-a potential inhibitor of COVID-19 main protease based on molecular docking”, Int. J. of Res. in Pharmacology &Pharmacotherapeutics , vol. 9, no. 2, pp. 136–144, Mar. 2021, doi: 10.61096/ijrpp.v9.iss2.2020.136-144.